[Evaluation of bone loss in patient treated with Gn-Rh analogs]

Minerva ginecologica · 1997 · vol. 49(6) , pp. 255–9 · PMID:9289664 · W2408247461
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-11-18 ⓘ

A prospective study of 38 patients with endometriosis or uterine fibromyomatosis treated with triptorelin found a mean bone mass loss of approximately 3% after six months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The increasing use of analogs of Gn-RH during treatment of some benign gynaecological diseases, has induced the authors to investigate the principal collateral effects, fixing one's attention on the loss of bony mass. METHODS: This perspective research has considered 38 patients selected for two diseases "endometriosis" and "uterine fibromyomatosis". The therapy has been effected with triptorelin intramuscularly in a dose of 3.75 mg every 28 days for six months, in all six phials. RESULTS: After a half-yearly cycle of therapy, the loss of bony mass was valued about 3% medium. CONCLUSIONS: In the light of other studies too, it was decided to confirm the necessity of associating other medicines able to prevent the side effects caused by their analogs of Gn-RH.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Genital Diseases, Female Genital Neoplasms, Female Growth Hormone-Releasing Hormone Osteoporosis Triptorelin Pamoate Adult Adult Bone Density Bone Density Endometriosis Endometriosis Endometriosis Female Female Fibroma Fibroma Fibroma Genital Diseases, Female Genital Diseases, Female

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-20T06:18:20.042577+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T22:00:22.376048+00:00
License: CC0 · commercial use OK